This Page Intentionally Left Blank - Int Medical

Sickle cell crisis 377
17. Jacob E, Miaskowski C, Savedra M, et al. Management of vaso-occlusive pain in
children with sickle cell disease. J Pediatr Hematol Oncol. 2003;25(4):307–311.
18. Gillis JC, Brogden RN. Ketorolac. A reappraisal of its pharmacodynamic and
pharmacokinetic properties and therapeutic use in pain management. Drugs.
1997;53(1):139–188.
19. Beiter JL, Jr., Simon HK, Chambliss CR, et al. Intravenous ketorolac in the
emergency department management of sickle cell pain and predictors of its
effectiveness. Arch Pediatr Adolesc Med. 2001;155(4):496–500.
20. Cordner S, De Ceulaer K. Musculoskeletal manifestations of hemoglobinopathies.
Curr Opin Rheumatol. 2003;15(1):44–47.
21. Hardwick WE, Jr., Givens TG, Monroe KW, et al. Effect of ketorolac in
pediatric sickle cell vaso-occlusive pain crisis. Pediatr Emerg Care. 1999;15
(3):179–182.
22. Perlin E, Finke H, Castro O, et al. Enhancement of pain control with ketorolac
tromethamine in patients with sickle cell vaso-occlusive crisis. Am J Hematol.
1994;46(1):43–47.
23. Wright SW, Norris RL, Mitchell TR. Ketorolac for sickle cell vaso-occlusive
crisis pain in the emergency department: lack of a narcotic-sparing effect. Ann
Emerg Med. 1992;21(8):925–928.
24. Simckes AM, Chen SS, Osorio AV, et al. Ketorolac-induced irreversible renal
failure in sickle cell disease: a case report. Pediatr Nephrol. 1999; 13(1):63–67.
25. Hick JL, Nelson SC, Hick K, et al. Emergency management of sickle cell
disease complications: review and practice guidelines. Minn Med. 2006; 89
(2):42–44, 47.
26. Platt A, Eckman JR, Beasley J, et al. Treating sickle cell pain: an update from the
Georgia comprehensive sickle cell center. J Emerg Nurs. 2002;28(4):297–303.
27. Koumoukelis H. Paediatric Pain Management Dosing Guideline. Toronto, ON:
Department of Anaesthesia, Toronto Hospital for Sick Children, 2002.
28. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates
and risk factors. N Engl J Med. 1991;325(1):11–16.
29. Kopecky EA, Jacobson S, Joshi P, et al. Systemic exposure to morphine and the
risk of acute chest syndrome in sickle cell disease. Clin Pharmacol Ther.
2004;75(3):140–146.
30. Nadvi SZ, Sarnaik S, Ravindranath Y. Low frequency of meperidine-associated
seizures in sickle cell disease. Clin Pediatr (Philadelphia). 1999; 38(8):459–462.
31. Turner E, Shapiro B. Pharmacological management of pain. In Shapiro B,
Schechter NL, Ohene-Frempong K (eds.) The Genetic Resource for Sickle Cell